Modern treatment of vulvar cancer

Sebastjan Merlo, Sebastjan Merlo

Abstract

Background Vulvar cancer accounts for 3-5% of malignant diseases of the female genital tract. The Slovenian incidence rate is 5.5/100,000, which means 57 new cases per year. The most common histological type (90%) is squamous cell carcinoma. Based on etiology, it can be classified into the first type which correlates with human papillomavirus (HPV) infection and the second type which is not associated with HPV. The most common and long-lasting symptom of vulvar cancer is pruritus. The preferred diagnostic procedure to confirm the diagnosis is a punch or incision biopsy. Surgery in combination with radiotherapy is the standard treatment for vulvar cancer. Sentinel lymph node biopsy with lymphoscintigraphy is now a standard part of surgical treatment. Chemotherapy is a palliative treatment option. Conclusions Vulvar cancer is a rare disease. Because of the pathogenesis, surgery and radiotherapy are the main treatment modalities. The sentinel node biopsy (SNB) represents a contemporary approach to the vulvar cancer treatment and significantly reduces morbidity. Improvements in treatment of vulvar cancer contributed to the decrease of mortality among Slovenian women.

Keywords: lymphoscintigraphy; radiotherapy; sentinel lymph node biopsy; surgical treatment; vulvar cancer.

References

    1. Alkatout I, Schubert M, Garbrecht N, Weigel MT, Jonat W, Mundhenke C. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health. 2015;7:305–13. doi: 10.2147/IJWH.S68979. et al.
    1. Oonk MHM, Planchamp F, Baldwin P, Bidzinski M, Brännström M, Landoni F. European Society of Gynaecological Oncology Guidelines for the management of patients with vulvar cancer. Int J Gynecol Cancer. 2017;27:832–7. doi: 10.1097/IGC.0000000000000975. et al.
    1. Cancer Registry of Republic of Slovenia [Internet] 2016. [cited 2020 May 6]. Available from.
    1. Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol. 2017;51:47–55. doi:1 0.1515/raon-2017-0008.
    1. Cancer in Slovenia. Ljubljana: Cancer in Slovenia 2016. Ljubljana: Institute of Oncology Ljubljana; 2016. Epidemiology and Cancer Registry, Slovenian Cancer Registry; [internet] 2019 [cited 2020 May 12]. Available from.
    1. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:23–34. doi: 10.1016/S1470-2045(13)70546-1. et al.
    1. Del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology. 2013;62:161–75. doi: 10.1111/his.12034.
    1. Pils S, Gensthaler L, Alemany L, Horvat R, de Sanjosé S, Joura EA. HPV prevalence in vulvar cancer in Austria. Wien Klin Wochenschr. 2017;129:805–9. doi: 10.1007/s00508-017-1255-2.
    1. Wohlmuth C, Wohlmuth-Wieser I. Vulvar malignancies: an interdisciplinary perspective. J Dtsch Dermatol Ges. 2019;17:1257–76. doi: 10.1111/ddg.13995.
    1. Angelico G, Santoro A, Inzani F, Spadola S, Fiorentino V, Cianfrini F. Ultrasound-guided FNA cytology of groin lymph nodes improves the management of squamous cell carcinoma of the vulva: results from a comparative cytohistological study. Cancer Cytopathol. 2019;127:514–20. doi: 10.1002/cncy.22154. et al.
    1. de Gregorio N, Ebner F, Schwentner L, Friedl TWP, Deniz M, Látó K, et al. The role of preoperative ultrasound evaluation of inguinal lymph nodes in patients with vulvar malignancy. Gynecol Oncol. 2013;131:113–7. doi: 10.1016/j.ygyno.2013.07.103.
    1. Kataoka MY, Sala E, Baldwin P, Reinhold C, Farhadi A, Hudolin T. The accuracy of magnetic resonance imaging in staging of vulvar cancer: a retrospective multi-centre study. Gynecol Oncol. 2010;117:82–7. doi: 10.1016/j.ygyno.2009.12.017. et al.
    1. Andersen K, Zobbe V, Thranov IR, Pedersen KD. Relevance of computerized tomography in the preoperative evaluation of patients with vulvar cancer: a prospective study. Cancer Imaging. 2015;15:8. doi: 10.1186/s40644-015-0044-2. Available from.
    1. Cham S, Chen L, Burke WM, Hou JY, Tergas AI, Hu JC. Utilization and outcomes of sentinel lymph node Biopsy for vulvar cancer. Obstet Gynecol. 2016;128:754–60. doi: 10.1097/AOG.0000000000001648. et al.
    1. Huang J, Yu N, Wang X, Long X. Incidence of lower limb lymphedema after vulvar cancer: a systematic review and meta-analysis. Medicine. 2017;96:8722. doi: 10.1097/MD.0000000000008722.
    1. Slomovitz BM, Coleman RL, Oonk MHM, van der Zee A, Levenback C. Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecol Oncol. 2015;138:472–7. doi: 10.1016/j.ygyno.2015.05.017.
    1. Oonk MHM, Hollema H, van der Zee AGJ. Sentinel node biopsy in vulvar cancer: implications for staging. Best Pract Res Clin Obstet Gynaecol. 2015;29:812–21. doi: 10.1016/j.bpobgyn.2015.03.007.
    1. Zigras T, Kupets R, Barbera L, Covens A, Liu Y, Gien LT. Uptake of sentinel lymph node procedures in women with vulvar cancer over time in a population based study. Gynecol Oncol. 2019;153:574–9. doi: 10.1016/j.ygyno.2019.03.010.
    1. Brincat MR, Muscat Baron Y. Sentinel lymph node biopsy in the management of vulvar carcinoma: an evidence-based insight. Int J Gynecol Cancer. 2017;27:1769–73. doi: 10.1097/IGC.0000000000001075.
    1. van Doorn HC, van Beekhuizen HJ, Gaarenstroom KN, van der Velden J, van der Zee AGJ, Oonk MHM, et al. Repeat sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma is feasible. Gynecol Oncol. 2016;140:415–9. doi: 10.1016/j.ygyno.2016.01.013.
    1. Verbeek FPR, Tummers QRJG, Rietbergen DDD, Peters AAW, Schaafsma BE, van de Velde CJH. Sentinel lymph node biopsy in vulvar cancer using combined radioactive and fluorescence guidance. Int J Gynecol Cancer. 2015;25:1086–93. doi: 10.1097/IGC.0000000000000419. et al.
    1. Ghoniem K, Shazly SA, Dinoi G, Zanfagnin V, Glaser GE, Mariani A. Sentinel lymph nodes and precision surgery in gynecologic cancer. Clin Obstet Gynecol. 2020;63:12–23. doi: 10.1097/GRF.0000000000000517.
    1. Van der Zee AGJ, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26:884–9. doi: 10.1200/JCO.2007.14.0566. et al.
    1. Mitra S, Sharma MK, Kaur I, Khurana R, Modi KB, Narang R. Vulvar carcinoma: dilemma, debates, and decisions. Cancer Manag Res. 2018;10:61–8. doi: 10.2147/CMAR.S143316. et al.
    1. Swanick CW, Eifel PJ, Huo J, Meyer LA, Smith GL. Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer. Gynecol Oncol. 2017;146:87–93. doi: 10.1016/j.ygyno.2017.05.004.
    1. Deppe G, Mert I, Belotte J, Winer IS. Chemotherapy of vulvar cancer: a review. Wien Klin Wochenschr. 2013;125:119–28. doi: 10.1007/s00508-013-0338-y.
    1. Domingues AP, Mota F, Durão M, Frutuoso C, Amaral N, de Oliveira CF. Neoadjuvant chemotherapy in advanced vulvar cancer. Int J Gynecol Cancer. 2010;20:294–8. doi: 10.1111/igc.0b013e3181c93adc.
    1. Inrhaoun H, Elghissassi I, Gutierrez M, Brain E, Errihani H. Long term response to erlotinib in a patient with recurrent vulvar carcinoma: case report and review of literature. Gynecol Oncol Case Rep. 2012;2:119–20. doi: 10.1016/j.gynor.2012.07.002.
    1. Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecologic Oncology. 2012;127:141–6. doi: 10.1016/j.ygyno.2012.06.028. et al.
    1. Schnürch HG, Ackermann S, Alt-Radtke CD, Angleitner L, Barinoff J, Beckmann MW. Diagnosis, therapy and follow-up of vaginal cancer and its precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October. 2018;2019;79:1060–78. doi: 10.1055/a-0919-4959. et al. Geburtshilfe Frauenheilk.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa